nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL22—psoriasis	0.0369	0.192	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—REN—psoriasis	0.0316	0.164	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—ACE—psoriasis	0.0197	0.103	CbGpPWpGaD
Azilsartan medoxomil—Telmisartan—PPARG—psoriasis	0.0157	0.677	CrCbGaD
Azilsartan medoxomil—Oedema peripheral—Tazarotene—psoriasis	0.0144	0.0183	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Acitretin—psoriasis	0.0142	0.018	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Clobetasol propionate—psoriasis	0.0122	0.0155	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Clobetasol propionate—psoriasis	0.0122	0.0155	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Hydroxyurea—psoriasis	0.0118	0.015	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Hydroxyurea—psoriasis	0.0111	0.0142	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Calcitriol—psoriasis	0.0106	0.0135	CcSEcCtD
Azilsartan medoxomil—Pruritus—Calcipotriol—psoriasis	0.00995	0.0127	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Mycophenolic acid—psoriasis	0.00986	0.0126	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Acitretin—psoriasis	0.00946	0.0121	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Mycophenolic acid—psoriasis	0.00931	0.0119	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Clobetasol propionate—psoriasis	0.00911	0.0116	CcSEcCtD
Azilsartan medoxomil—Angioedema—Beclomethasone—psoriasis	0.00896	0.0114	CcSEcCtD
Azilsartan medoxomil—Rash—Calcipotriol—psoriasis	0.00887	0.0113	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Calcipotriol—psoriasis	0.00886	0.0113	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Clobetasol propionate—psoriasis	0.00854	0.0109	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Fluocinonide—psoriasis	0.00821	0.0105	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Cyclosporine—psoriasis	0.00798	0.0102	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Mycophenolate mofetil—psoriasis	0.00778	0.00991	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Fluocinonide—psoriasis	0.00778	0.00991	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Fluocinonide—psoriasis	0.0077	0.00981	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Cyclosporine—psoriasis	0.00753	0.0096	CcSEcCtD
Azilsartan medoxomil—Losartan—ACE—psoriasis	0.00751	0.323	CrCbGaD
Azilsartan medoxomil—Blood creatinine increased—Hydroxyurea—psoriasis	0.00743	0.00946	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Methoxsalen—psoriasis	0.00737	0.00939	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Mycophenolate mofetil—psoriasis	0.00735	0.00936	CcSEcCtD
Azilsartan medoxomil—Pruritus—Tazarotene—psoriasis	0.00734	0.00935	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-C—psoriasis	0.007	0.0365	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL13—psoriasis	0.00695	0.0362	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Acitretin—psoriasis	0.00688	0.00877	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Fluocinolone Acetonide—psoriasis	0.00684	0.00872	CcSEcCtD
Azilsartan medoxomil—Rash—Tazarotene—psoriasis	0.00654	0.00833	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Tazarotene—psoriasis	0.00653	0.00832	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL17A—psoriasis	0.0064	0.0334	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Acitretin—psoriasis	0.00634	0.00807	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Mycophenolic acid—psoriasis	0.00622	0.00792	CcSEcCtD
Azilsartan medoxomil—Pruritus—Clobetasol propionate—psoriasis	0.00622	0.00792	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Methoxsalen—psoriasis	0.00608	0.00774	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL12B—psoriasis	0.00595	0.031	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Acitretin—psoriasis	0.00585	0.00745	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-E—psoriasis	0.00581	0.0303	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00564	0.0294	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Fluocinonide—psoriasis	0.00561	0.00715	CcSEcCtD
Azilsartan medoxomil—Angioedema—Acitretin—psoriasis	0.00556	0.00708	CcSEcCtD
Azilsartan medoxomil—Rash—Clobetasol propionate—psoriasis	0.00554	0.00706	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Clobetasol propionate—psoriasis	0.00554	0.00705	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Calcitriol—psoriasis	0.00542	0.0069	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Methoxsalen—psoriasis	0.0054	0.00688	CcSEcCtD
Azilsartan medoxomil—Dizziness—Beclomethasone—psoriasis	0.00529	0.00674	CcSEcCtD
Azilsartan medoxomil—Dizziness—Fluocinonide—psoriasis	0.00524	0.00668	CcSEcCtD
Azilsartan medoxomil—Rash—Beclomethasone—psoriasis	0.00505	0.00643	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Beclomethasone—psoriasis	0.00504	0.00642	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Cyclosporine—psoriasis	0.00503	0.00641	CcSEcCtD
Azilsartan medoxomil—Rash—Fluocinonide—psoriasis	0.005	0.00637	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Fluocinonide—psoriasis	0.00499	0.00636	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Hydroxyurea—psoriasis	0.00498	0.00634	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Mycophenolate mofetil—psoriasis	0.00491	0.00625	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Fluocinolone Acetonide—psoriasis	0.00485	0.00618	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Acitretin—psoriasis	0.00482	0.00614	CcSEcCtD
Azilsartan medoxomil—Nausea—Beclomethasone—psoriasis	0.00475	0.00606	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Mycophenolic acid—psoriasis	0.00452	0.00576	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Mycophenolic acid—psoriasis	0.00451	0.00575	CcSEcCtD
Azilsartan medoxomil—Pruritus—Methoxsalen—psoriasis	0.00443	0.00564	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Methotrexate—psoriasis	0.00441	0.00562	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCL20—psoriasis	0.00436	0.0227	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL10—psoriasis	0.00435	0.0227	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—HCAR2—psoriasis	0.00429	0.0224	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Acitretin—psoriasis	0.00428	0.00546	CcSEcCtD
Azilsartan medoxomil—Fatigue—Acitretin—psoriasis	0.00428	0.00545	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.00427	0.00544	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL4—psoriasis	0.00423	0.0221	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Mycophenolic acid—psoriasis	0.00417	0.00531	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Methotrexate—psoriasis	0.00416	0.0053	CcSEcCtD
Azilsartan medoxomil—Dizziness—Methoxsalen—psoriasis	0.00414	0.00527	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-B—psoriasis	0.00414	0.0216	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.00404	0.00514	CcSEcCtD
Azilsartan medoxomil—Asthenia—Calcitriol—psoriasis	0.004	0.0051	CcSEcCtD
Azilsartan medoxomil—Pruritus—Calcitriol—psoriasis	0.00395	0.00503	CcSEcCtD
Azilsartan medoxomil—Rash—Methoxsalen—psoriasis	0.00395	0.00503	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Methoxsalen—psoriasis	0.00394	0.00502	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Mycophenolic acid—psoriasis	0.00384	0.0049	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-A—psoriasis	0.00383	0.02	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Hydroxyurea—psoriasis	0.00382	0.00487	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Calcitriol—psoriasis	0.00382	0.00486	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Hydroxyurea—psoriasis	0.00378	0.00482	CcSEcCtD
Azilsartan medoxomil—Nausea—Methoxsalen—psoriasis	0.00372	0.00474	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Cyclosporine—psoriasis	0.00365	0.00465	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Mycophenolate mofetil—psoriasis	0.00357	0.00455	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.00356	0.00454	CcSEcCtD
Azilsartan medoxomil—Asthenia—Acitretin—psoriasis	0.00356	0.00454	CcSEcCtD
Azilsartan medoxomil—Rash—Calcitriol—psoriasis	0.00352	0.00448	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Calcitriol—psoriasis	0.00351	0.00448	CcSEcCtD
Azilsartan medoxomil—Pruritus—Acitretin—psoriasis	0.00351	0.00447	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—HLA-DRB1—psoriasis	0.0035	0.0183	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Fluocinolone Acetonide—psoriasis	0.0035	0.00446	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Acitretin—psoriasis	0.0034	0.00433	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00339	0.00431	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.00338	0.00431	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Cyclosporine—psoriasis	0.00337	0.00429	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.00336	0.00429	CcSEcCtD
Azilsartan medoxomil—Fatigue—Hydroxyurea—psoriasis	0.00336	0.00428	CcSEcCtD
Azilsartan medoxomil—Nausea—Calcitriol—psoriasis	0.00331	0.00422	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Mycophenolate mofetil—psoriasis	0.00329	0.00419	CcSEcCtD
Azilsartan medoxomil—Dizziness—Acitretin—psoriasis	0.00328	0.00418	CcSEcCtD
Azilsartan medoxomil—Dizziness—Fluocinolone Acetonide—psoriasis	0.00327	0.00417	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Hydrocortisone—psoriasis	0.00324	0.00413	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Mycophenolic acid—psoriasis	0.0032	0.00408	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Mycophenolic acid—psoriasis	0.00317	0.00404	CcSEcCtD
Azilsartan medoxomil—Rash—Acitretin—psoriasis	0.00313	0.00399	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Acitretin—psoriasis	0.00313	0.00398	CcSEcCtD
Azilsartan medoxomil—Rash—Fluocinolone Acetonide—psoriasis	0.00312	0.00398	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Fluocinolone Acetonide—psoriasis	0.00312	0.00397	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Cyclosporine—psoriasis	0.00311	0.00396	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NFKB1—psoriasis	0.00307	0.016	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Mycophenolate mofetil—psoriasis	0.00303	0.00386	CcSEcCtD
Azilsartan medoxomil—Angioedema—Cyclosporine—psoriasis	0.00296	0.00377	CcSEcCtD
Azilsartan medoxomil—Nausea—Acitretin—psoriasis	0.00295	0.00376	CcSEcCtD
Azilsartan medoxomil—Nausea—Fluocinolone Acetonide—psoriasis	0.00294	0.00374	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00293	0.0153	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Mycophenolate mofetil—psoriasis	0.00288	0.00367	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.00282	0.00359	CcSEcCtD
Azilsartan medoxomil—Fatigue—Mycophenolic acid—psoriasis	0.00281	0.00358	CcSEcCtD
Azilsartan medoxomil—Asthenia—Hydroxyurea—psoriasis	0.0028	0.00356	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.00273	0.00348	CcSEcCtD
Azilsartan medoxomil—Angioedema—Prednisolone—psoriasis	0.00269	0.00343	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.00267	0.0034	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Hydroxyurea—psoriasis	0.00267	0.0034	CcSEcCtD
Azilsartan medoxomil—Angioedema—Hydrocortisone—psoriasis	0.00263	0.00335	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Cyclosporine—psoriasis	0.00259	0.0033	CcSEcCtD
Azilsartan medoxomil—Dizziness—Hydroxyurea—psoriasis	0.00258	0.00328	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Cyclosporine—psoriasis	0.00256	0.00327	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Dexamethasone—psoriasis	0.00256	0.00326	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Betamethasone—psoriasis	0.00256	0.00326	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IFNG—psoriasis	0.00256	0.0133	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.00253	0.00322	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Mycophenolate mofetil—psoriasis	0.0025	0.00319	CcSEcCtD
Azilsartan medoxomil—Angioedema—Triamcinolone—psoriasis	0.00247	0.00315	CcSEcCtD
Azilsartan medoxomil—Rash—Hydroxyurea—psoriasis	0.00246	0.00313	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Hydroxyurea—psoriasis	0.00245	0.00313	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.00243	0.0031	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—HCAR2—psoriasis	0.00243	0.0126	CbGpPWpGaD
Azilsartan medoxomil—Connective tissue disorder—Prednisone—psoriasis	0.00241	0.00308	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriasis	0.00239	0.0124	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL8—psoriasis	0.00238	0.0124	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Mycophenolic acid—psoriasis	0.00234	0.00298	CcSEcCtD
Azilsartan medoxomil—Nausea—Hydroxyurea—psoriasis	0.00231	0.00295	CcSEcCtD
Azilsartan medoxomil—Pruritus—Mycophenolic acid—psoriasis	0.00231	0.00294	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Hydrocortisone—psoriasis	0.0023	0.00293	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Cyclosporine—psoriasis	0.00228	0.0029	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Hydrocortisone—psoriasis	0.00228	0.0029	CcSEcCtD
Azilsartan medoxomil—Fatigue—Cyclosporine—psoriasis	0.00228	0.0029	CcSEcCtD
Azilsartan medoxomil—Angioedema—Betamethasone—psoriasis	0.00224	0.00286	CcSEcCtD
Azilsartan medoxomil—Angioedema—Dexamethasone—psoriasis	0.00224	0.00286	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Mycophenolic acid—psoriasis	0.00223	0.00284	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCL20—psoriasis	0.00223	0.0116	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Prednisone—psoriasis	0.00223	0.00284	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.00222	0.00283	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HCAR2—psoriasis	0.0022	0.0115	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Mycophenolic acid—psoriasis	0.00216	0.00275	CcSEcCtD
Azilsartan medoxomil—Rash—Mycophenolic acid—psoriasis	0.00206	0.00262	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Mycophenolic acid—psoriasis	0.00206	0.00262	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.00203	0.00258	CcSEcCtD
Azilsartan medoxomil—Fatigue—Hydrocortisone—psoriasis	0.00202	0.00258	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Betamethasone—psoriasis	0.00197	0.0025	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Dexamethasone—psoriasis	0.00197	0.0025	CcSEcCtD
Azilsartan medoxomil—Angioedema—Prednisone—psoriasis	0.00195	0.00249	CcSEcCtD
Azilsartan medoxomil—Nausea—Mycophenolic acid—psoriasis	0.00194	0.00247	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—psoriasis	0.00193	0.0101	CbGpPWpGaD
Azilsartan medoxomil—Fatigue—Triamcinolone—psoriasis	0.0019	0.00243	CcSEcCtD
Azilsartan medoxomil—Asthenia—Cyclosporine—psoriasis	0.00189	0.00241	CcSEcCtD
Azilsartan medoxomil—Pruritus—Cyclosporine—psoriasis	0.00187	0.00238	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Methotrexate—psoriasis	0.00186	0.00237	CcSEcCtD
Azilsartan medoxomil—Asthenia—Mycophenolate mofetil—psoriasis	0.00185	0.00235	CcSEcCtD
Azilsartan medoxomil—Pruritus—Mycophenolate mofetil—psoriasis	0.00182	0.00232	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.00181	0.0023	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Cyclosporine—psoriasis	0.00181	0.0023	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00176	0.00224	CcSEcCtD
Azilsartan medoxomil—Dizziness—Cyclosporine—psoriasis	0.00175	0.00222	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Betamethasone—psoriasis	0.00173	0.0022	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00173	0.0022	CcSEcCtD
Azilsartan medoxomil—Fatigue—Dexamethasone—psoriasis	0.00173	0.0022	CcSEcCtD
Azilsartan medoxomil—Fatigue—Betamethasone—psoriasis	0.00173	0.0022	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Prednisone—psoriasis	0.00171	0.00218	CcSEcCtD
Azilsartan medoxomil—Dizziness—Mycophenolate mofetil—psoriasis	0.0017	0.00217	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Prednisone—psoriasis	0.0017	0.00216	CcSEcCtD
Azilsartan medoxomil—Asthenia—Hydrocortisone—psoriasis	0.00168	0.00214	CcSEcCtD
Azilsartan medoxomil—Rash—Cyclosporine—psoriasis	0.00166	0.00212	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Cyclosporine—psoriasis	0.00166	0.00212	CcSEcCtD
Azilsartan medoxomil—Pruritus—Hydrocortisone—psoriasis	0.00166	0.00211	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—psoriasis	0.00166	0.00863	CbGpPWpGaD
Azilsartan medoxomil—Rash—Mycophenolate mofetil—psoriasis	0.00162	0.00207	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Mycophenolate mofetil—psoriasis	0.00162	0.00207	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Hydrocortisone—psoriasis	0.00161	0.00205	CcSEcCtD
Azilsartan medoxomil—Dizziness—Prednisolone—psoriasis	0.00159	0.00202	CcSEcCtD
Azilsartan medoxomil—Asthenia—Triamcinolone—psoriasis	0.00158	0.00202	CcSEcCtD
Azilsartan medoxomil—Nausea—Cyclosporine—psoriasis	0.00157	0.002	CcSEcCtD
Azilsartan medoxomil—Pruritus—Triamcinolone—psoriasis	0.00156	0.00199	CcSEcCtD
Azilsartan medoxomil—Dizziness—Hydrocortisone—psoriasis	0.00155	0.00198	CcSEcCtD
Azilsartan medoxomil—Nausea—Mycophenolate mofetil—psoriasis	0.00153	0.00195	CcSEcCtD
Azilsartan medoxomil—Rash—Prednisolone—psoriasis	0.00151	0.00193	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Prednisolone—psoriasis	0.00151	0.00193	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.00151	0.00193	CcSEcCtD
Azilsartan medoxomil—Fatigue—Prednisone—psoriasis	0.0015	0.00192	CcSEcCtD
Azilsartan medoxomil—Rash—Hydrocortisone—psoriasis	0.00148	0.00188	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Hydrocortisone—psoriasis	0.00148	0.00188	CcSEcCtD
Azilsartan medoxomil—Dizziness—Triamcinolone—psoriasis	0.00146	0.00186	CcSEcCtD
Azilsartan medoxomil—Asthenia—Betamethasone—psoriasis	0.00144	0.00183	CcSEcCtD
Azilsartan medoxomil—Asthenia—Dexamethasone—psoriasis	0.00144	0.00183	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Methotrexate—psoriasis	0.00143	0.00182	CcSEcCtD
Azilsartan medoxomil—Nausea—Prednisolone—psoriasis	0.00143	0.00182	CcSEcCtD
Azilsartan medoxomil—Pruritus—Betamethasone—psoriasis	0.00142	0.00181	CcSEcCtD
Azilsartan medoxomil—Pruritus—Dexamethasone—psoriasis	0.00142	0.00181	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Methotrexate—psoriasis	0.00142	0.00181	CcSEcCtD
Azilsartan medoxomil—Nausea—Hydrocortisone—psoriasis	0.00139	0.00178	CcSEcCtD
Azilsartan medoxomil—Rash—Triamcinolone—psoriasis	0.00139	0.00177	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Triamcinolone—psoriasis	0.00139	0.00177	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Dexamethasone—psoriasis	0.00137	0.00175	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Betamethasone—psoriasis	0.00137	0.00175	CcSEcCtD
Azilsartan medoxomil—Dizziness—Betamethasone—psoriasis	0.00133	0.00169	CcSEcCtD
Azilsartan medoxomil—Dizziness—Dexamethasone—psoriasis	0.00133	0.00169	CcSEcCtD
Azilsartan medoxomil—Nausea—Triamcinolone—psoriasis	0.00131	0.00167	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HCAR2—psoriasis	0.0013	0.00678	CbGpPWpGaD
Azilsartan medoxomil—Rash—Betamethasone—psoriasis	0.00126	0.00161	CcSEcCtD
Azilsartan medoxomil—Rash—Dexamethasone—psoriasis	0.00126	0.00161	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Dexamethasone—psoriasis	0.00126	0.00161	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Betamethasone—psoriasis	0.00126	0.00161	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCL20—psoriasis	0.00126	0.00657	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Methotrexate—psoriasis	0.00126	0.0016	CcSEcCtD
Azilsartan medoxomil—Fatigue—Methotrexate—psoriasis	0.00126	0.0016	CcSEcCtD
Azilsartan medoxomil—Asthenia—Prednisone—psoriasis	0.00125	0.0016	CcSEcCtD
Azilsartan medoxomil—Pruritus—Prednisone—psoriasis	0.00123	0.00157	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.00123	0.00639	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Prednisone—psoriasis	0.00119	0.00152	CcSEcCtD
Azilsartan medoxomil—Nausea—Dexamethasone—psoriasis	0.00119	0.00152	CcSEcCtD
Azilsartan medoxomil—Nausea—Betamethasone—psoriasis	0.00119	0.00152	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL8—psoriasis	0.00118	0.00614	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Prednisone—psoriasis	0.00115	0.00147	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCL20—psoriasis	0.00114	0.00596	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TAGAP—psoriasis	0.00113	0.00588	CbGpPWpGaD
Azilsartan medoxomil—Rash—Prednisone—psoriasis	0.0011	0.0014	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Prednisone—psoriasis	0.0011	0.0014	CcSEcCtD
Azilsartan medoxomil—Asthenia—Methotrexate—psoriasis	0.00105	0.00133	CcSEcCtD
Azilsartan medoxomil—Nausea—Prednisone—psoriasis	0.00104	0.00132	CcSEcCtD
Azilsartan medoxomil—Pruritus—Methotrexate—psoriasis	0.00103	0.00131	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Methotrexate—psoriasis	0.000998	0.00127	CcSEcCtD
Azilsartan medoxomil—Dizziness—Methotrexate—psoriasis	0.000965	0.00123	CcSEcCtD
Azilsartan medoxomil—Rash—Methotrexate—psoriasis	0.00092	0.00117	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Methotrexate—psoriasis	0.000919	0.00117	CcSEcCtD
Azilsartan medoxomil—Nausea—Methotrexate—psoriasis	0.000866	0.0011	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000791	0.00412	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCL20—psoriasis	0.000676	0.00352	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL8—psoriasis	0.000602	0.00314	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	0.0006	0.00313	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SOCS1—psoriasis	0.000372	0.00194	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—TYK2—psoriasis	0.000355	0.00185	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL8—psoriasis	0.00034	0.00177	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL8—psoriasis	0.000309	0.00161	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LEP—psoriasis	0.000275	0.00143	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOE—psoriasis	0.000275	0.00143	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NFKBIA—psoriasis	0.000256	0.00133	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TYK2—psoriasis	0.00021	0.00109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL8—psoriasis	0.000182	0.000951	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—psoriasis	0.000174	0.000904	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JUN—psoriasis	0.00017	0.000884	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NFKB1—psoriasis	0.000163	0.000851	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—psoriasis	0.000148	0.000773	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT3—psoriasis	0.000147	0.000765	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TP53—psoriasis	0.000112	0.000584	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—psoriasis	0.000103	0.000534	CbGpPWpGaD
